Benzalkonium chloride is commonly used as a preservative in ophthalmic products and has been reported rarely to cause punctate keratopathy and/or toxic ulcerative keratopathy.
Benzalkonium chloride may be absorbed by and discolour soft contact lenses and therefore, patients should be instructed to wait until 10-15 min after instillation of Relestat before inserting contact lenses. Relestat should not be administered while wearing contact lenses.
Effects on the Ability to Drive or Operate Machinery: Based on the pharmacodynamic profile, reported adverse reactions and specific psychometric studies, epinastine has no or negligible influence on the ability to drive and use machines. If transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.
Use in pregnancy: Data on a limited number (11) of exposed pregnancies indicate no adverse effects of epinastine on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development (see Toxicology under Actions).
Caution should be exercised when prescribing to pregnant women.
Use in lactation: Epinastine is excreted in the breast milk of rats, but it is not known if epinastine is excreted in human milk. Due to the lack of experience, caution should be exercised when prescribing to breastfeeding women.